29 Apr 2023 - 30 Apr 2023
08:55 AM - 01:50 PM
04th Knowledge Series for Genitourinary Cancers - Year In Review
Program Director: Dr Kumar Prabhash
Day - 1 - 29 April 2023 - Session 2
Date : 29 Apr 2023
| Pooled outcomes of performing freehand transperineal prostate biopsy with the PrecisionPoint Transperineal Access System(BJUI Compass. 2022 Jun) | 10:45 AM - 10:55 AM |
| Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience | 10:55 AM - 11:05 AM |
| Superior Post-Treatment Biopsy Outcomes with High Dose SBRT Compared to High-Dose Conventionally Fractionated IMRT for Clinically Localized Prostate Cancer | 11:05 AM - 11:15 AM |
| FORMULA-509: A multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with or without abiraterone acetate/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP). (oral abstract 303) | 11:15 AM - 11:25 AM |
| Sequencing of Androgen Deprivation Therapy of Short Duration with Radiotherapy for Non-Metastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials | 11:25 AM - 11:35 AM |
| Impact of PSMA PET/CT on Prostate Cancer Salvage Radiotherapy Management: Results from the Prospective Randomized Phase 3 Trial [PSMA SRT NCT03582774] | 11:35 AM - 11:45 AM |
| Panel Discussion | 11:45 AM - 12:25 PM |
Day - 1 - 29 April 2023 - Session 3
Date : 29 Apr 2023
| Feasibility and safety of radical prostatectomy for oligo- metastatic prostate cancer: theTesting Radical prostatectomy in men with prostate cancer and oligo-Metastases to the bone (TRoMbone) trial | 12:30 PM - 12:40 PM |
| Efficiency and safety of Thalidomide in combination with ADT and Docetaxel | 12:40 PM - 12:50 PM |
| TALAPRO-2: Phase 3 Study of Talazoparib + Enzalutamide Versus Placebo + ENZA as First-Line Treatment in Patients with mCRPC, | 12:50 PM - 01:05 PM |
| - Pembrolizumab + olaparib vs abiraterone (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC): Randomized open-label phase III KEYLYNK-010 study | 01:05 PM - 01:15 PM |
| Early results from a phase 1, multicenter trial of PSCA-specific GoCAR T cells (BPX601) in patients with metastatic castration-resistant prostate cancer (mCRPC). (poster 140) | 01:15 PM - 01:25 PM |
| 177Lu-PSMA-617 (LuPSMA) Versus Cabazitaxel in mCRPC Progressing After Docetaxel—Overall Survival After Median Follow-Up of 3 Years (ANZUP 1603) - TheraP | 01:25 PM - 01:35 PM |
| NRG-GU011: A Phase II Double-Blinded, Placebo-Controlled Trial of Prostate Oligometastatic Radiotherapy with or Without Androgen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG PROMETHEAN) | 01:35 PM - 01:45 PM |
| Panel Discussion | 01:45 PM - 02:15 PM |
| Expert Comment | 02:15 PM - 02:20 PM |
Day - 1 - 29 April 2023 - Session 4
Date : 29 Apr 2023
| Renal cell carcinoma in renal transplant recipients : Is there a role of screening? | 03:05 PM - 03:15 PM |
| Development and Validation of a Nomogram Predicting Intraoperative Adverse Events During Robot-assisted Partial Nephrectomy: | 03:15 PM - 03:25 PM |
| Identifying patients for adjuvant therapy after nephrectomy U capitanio: lancet 2022 | 03:25 PM - 03:35 PM |
| Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with eckpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium | 03:35 PM - 03:45 PM |
| Bone Only Oligometastatic Renal Cell Carcinoma Patients Treated with Stereotactic Body Radiotherapy: A MULTI-Institutional Study | 03:45 PM - 03:55 PM |
| Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System | 03:55 PM - 04:05 PM |
| Panel Discussion | 04:05 PM - 04:45 PM |
| Expert Comment | 04:45 PM - 04:50 PM |
Industry Symposium - Day 1 - 29 April 2023
Date : 29 Apr 2023
Program Director:
Dr Kumar Prabhash
Contact Person
Garima Vashishtha
info@hcmpl.com
8178985238
Download